03 Feb 2020 --- Biopharmaceutical company Aimmune Therapeutics has received US Food and Drug Administration (FDA) approval for Palforzia, the first approved oral immunotherapy treatment for patients with peanut allergies. Treatment with Palforzia involves administering small amounts of peanuts to increase tolerance to the legume, which can help reduce the severity of allergic reactions such as anaphylaxis. Initial dose escalation can be administered to patients aged four through 17 years and may be continued in individuals four years of age and older – crucial, as both peanut allergy cases in children and their awareness have risen in the past decade.
